Condition: Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia · Sponsor: Kissei Pharmaceutical Co., Ltd.
This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.
This description comes directly from the study's public registry record.
Kissei Pharmaceutical Co., Ltd · Email only · rinsyousiken@pharm.kissei.co.jp
Always discuss trial participation with your own doctor first.
| Research Site | Tokyo and Other Japanese Cities, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07604064